|Day Low/High||49.51 / 49.88|
|52 Wk Low/High||37.62 / 55.00|
Cempra and Relypsa are two high-risk, high-reward small-caps worth considering.
And four other things you need to know now.
TheStreet's Jim Cramer said to buy Priceline (PCLN) on the dip Monday while answering viewer questions from the floor of the New York Stock Exchange.
Stocks ended the day lower in a quieter session of trading compared to Wednesday's blowout rally.
Selection of stocks is tailor made for investor, given market parameters.
The European economy is growing and the volatility from the Greek exit drama is keeping a lid on stock valuations.
It's almost impossible to get too excited about its success.
As health-care stocks rally, it's time for politicians to move on.
These firms offer strong dividends, cash flow and trailing 12-month sales.
An inverse head and shoulders pattern could soon develop.
Syringe-seller Unilife is gaining momentum - and scaring the shorts - after signing a big deal with Sanofi, says Alan Shortall, CEO of Unilife.
Gladstone Land, KaloBios Pharmaceuticals and Stemline Therapeutics plan to go public, IPO Desktop President Francis Gaskins isn't sure the risk is worth it.
Jeanie Wyatt, CEO of South Texas Money Management, names her favorite stocks including Wells Fargo and Sanofi.
These drug companies addressing prostate cancer get high grades from my guru strategies.
This drugmaker has fallen from a nine-month high to a key support level in just five sessions.
Forest Labs has potential volatility and high short interest, and Sanofi has crossed some key levels.
Stephanie Link, director of research for TheStreet, explains why Sanofi is an attractive investment under $35.
Dan Fitzpatrick examines three stocks viewed on Fast Money. Today's stocks include Sanofi-Aventis, Cypress Semiconductor and Biogen.